Neoplas Med, a German medical technology company specializing in cold plasma therapy for wound healing, raised $18 million in funding from Niterra Co., Ltd. (formerly NGK Spark Plug Co., Ltd.) and Pegasus Tech Ventures.
Initial Funding Round: In July 2022, Neoplas Med secured its initial funding through a corporate venture capital investment from NGK Spark Plug Co., Ltd. (now known as Niterra Co., Ltd.).
Building on the initial partnership, in April 2023, Niterra expanded its strategic partnership with Neoplas Med through a growth investment aimed at supporting global expansion and product development.
Neoplas Med GmbH specializes in a medical technology called argon cold plasma therapy, which uses a device known as the kINPen® MED to improve wound healing. This technology applies a controlled jet of cold plasma—a state of matter created by energizing the inert gas argon—directly to wounds. The plasma has antimicrobial properties, meaning it can help reduce infection, while also stimulating tissue regeneration and accelerating healing.
The Neoplas Med approach is particularly effective for treating chronic wounds (long-lasting wounds that don’t heal naturally) and infected wounds. The company’s products are certified under the European Medical Device Regulation (MDR), making them compliant for clinical use across Europe.
Neoplas Med plans to use the fresh funds to accelerate international expansion and technology platform development for treating infected and chronic wounds.
In the official press announcement, Ulrike Sailer, CEO of Neoplas Med, stated: “With our new strategic partner, we get additional tailwind for the further development of our cold plasma jet technology into new fields of application for the needs of patients and the departure into new international markets.”